首页> 美国卫生研究院文献>Case Reports in Psychiatry >Phenibut (β-Phenyl-γ-aminobutyric Acid) Dependence and Management of Withdrawal: Emerging Nootropics of Abuse
【2h】

Phenibut (β-Phenyl-γ-aminobutyric Acid) Dependence and Management of Withdrawal: Emerging Nootropics of Abuse

机译:Phenibut(β-苯基-γ-氨基丁酸)依赖性和戒断管理:新兴的促智药物滥用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This case report describes the development of withdrawal from phenibut, a gamma-aminobutyric acid-receptor type B agonist. Although phenibut is not an FDA-approved medication, it is available through online retailers as a nootropic supplement. There are reports of dependence in patients that misuse phenibut. We report a case in which a patient experienced withdrawal symptoms from phenibut and was successfully treated with a baclofen taper. This case report highlights the development of phenibut use disorder with coingestion of alcohol and potential management for phenibut withdrawal. We believe clinicians must be aware of how phenibut dependence may present and how to manage the withdrawal syndrome.
机译:该病例报告描述了从苯丙酸氮芥(一种γ-氨基丁酸受体B型激动剂)中退出的情况。尽管非那非不是FDA批准的药物,但可以通过在线零售商作为促智补充剂获得。有滥用苯酚的患者有依赖性的报道。我们报告了一例患者经历了从苯丙氨酸戒断症状并成功用巴氯芬锥度治疗的情况。该病例报告突出了伴随着酒精共摄取的苯酚使用障碍的发展以及对苯酚治疗的潜在管理。我们认为,临床医生必须意识到可能存在苯依比依赖以及如何处理戒断综合征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号